Quick Answer
Cocrystal Pharma, Inc. reported Net Income Loss of -$8.83 million for the year ending 2025.
- Cocrystal Pharma, Inc. showed an increase of +49.5% in Net Income Loss from 2024 to 2025.
- This data is from Cocrystal Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Cocrystal Pharma, Inc.'s Net Income Loss has declined by 2,661.3%.
- Historical annual values: Fiscal year 2025: -$8.83 million | Fiscal year 2024: -$17.50 million | Fiscal year 2023: -$17.98 million | Fiscal year 2022: -$38.84 million | Fiscal year 2021: -$14.19 million | Fiscal year 2020: -$9.65 million | Fiscal year 2019: -$48.17 million | Fiscal year 2018: -$49.05 million | Fiscal year 2017: -$613.0 thousand | Fiscal year 2016: -$74.87 million | Fiscal year 2015: -$50.12 million | Fiscal year 2014: -$99.0 thousand | Fiscal year 2013: -$3.89 million | Fiscal year 2012: -$7.96 million | Fiscal year 2011: -$5.46 million | Fiscal year 2010: -$319.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: